Pyoderma Gangrenosum
Pyoderma gangrenosum is a rare inflammatory skin condition characterized by painful ulcers that can develop rapidly. It often occurs in people with underlying health issues and may require specialized treatment.
Ulcerative Pyoderma Gangrenosum: Spesolimab Study
We are testing whether spesolimab can help adults with ulcerative pyoderma gangrenosum heal their skin ulcers better than a placebo. This study aims to evaluate its safety and effectiveness.
What diseases are being studied?
Health conditions and diseases that the clinical trial is designed to study and treat.
Who can participate in the clinical trial?
These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..
- Are you at least 18 years old?
- Do you have a confirmed diagnosis of ulcerative pyoderma gangrenosum (PG)?
- Do you have at least one PG ulcer that measures 5 cm² or more?
- Have you had any active infections in the last 2 weeks?
- Are you a woman of childbearing potential and able to use effective birth control?
Where is the clinical trial being conducted?
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Loading map...
Medical University Of Graz
Univ.-Klinik f. Dermatologie und Venerologie
Graz, Austria
Johannes Kepler University Linz
University Clinic for Dermatology and Venereology
Linz, Austria
Clinical Research Center Salzburg GmbH
Universitätsklinik für Dermatologie und Allergologie
Salzburg, Austria
Sponsor: Boehringer Ingelheim International GmbH
Last updated: Nov 27, 2025
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.